Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New knee procedure aims to fill bone defects and ease pain

NCT ID NCT03112200

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a procedure called Subchondroplasty, which fills bone defects with a special material, plus standard knee arthroscopy works better than arthroscopy alone for treating bone marrow lesions in the knee. About 131 adults with knee pain and osteoarthritis took part. The main goal was to see if the combined approach reduced pain and the need for further surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AccuFill Bone Substitute Material (calcium phosphate)
What this could lead to
If it works, this could offer a better option for people with knee bone marrow lesions and osteoarthritis, potentially reducing pain and the need for more surgery.
What could go wrong
This is a completed trial with 131 participants, but it's a single study. The procedure is surgical and carries risks like infection or incomplete pain relief. Results may not apply to everyone with knee pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

131 people

The number who actually took part.

Started

Mar 2017

Finished

Aug 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Candidates must meet ALL of the following: 1. Voluntary signature of the Institutional Review Board/Research Ethics Board approved Informed Consent, 2. Male or female subjects between the ages of 30 to 75 years, 3. Body Mass Index ≤ 40 (BMI=kg/m2), 4. Has experienced pain in study knee for at least 3 months, 5. Kellgren-Lawrence grade 1-3 Osteoarthritis, as reviewed on preoperative XR imaging, in the study knee, 6. BML is confirmed on T2 weighted or Proton Density MR Imaging by presence of white signal, 7. Single BML of tibia, single BML of femur, or adjoining BML's of tibia \& femur, in the same compartment, extending to the articular surface of the joint, 8. Surgical candidate for knee arthroscopy due to mechanical symptoms, meniscus tear, loose body and/or synovitis, 9. Must record a response, at the preoperative study visit, of moderate to extreme pain for any one of the KOOS Pain Scale questions, P2 through P9, 10. Index knee alignment is defined radiographically as one of the following: Neutral, ≤ 6° mechanical varus, or ≤ 6° mechanical valgus, 11. Ligaments in the study knee are stable, 12. The contralateral (non-study) knee is stable and functional, 13. Is refractory to conservative non-surgical management 1. having failed 2 or more of the following: hyaluronic acid injection, corticosteroid injection, NSAIDs, physical therapy, bracing, activity modification, or minimal surgical intervention (e.g., arthroscopy, debridement/chondroplasty, and/or loose body removal) 2. and is ≥ 3 months from the start of treatment, 14. Must be physically and mentally willing and able, in the Investigator's opinion at the time of enrollment, to be compliant with the protocol - including all follow-up visits, survey completion, weight-bearing restrictions, and post-operative rehabilitation. Exclusion Criteria: * Candidates will be excluded if they meet ANY of the following: 1. BML caused by acute trauma less than 3 months prior to enrollment, 2. Clinical and/or radiographic disease diagnosis of the index knee that includes any of the following: 1. Kellgren-Lawrence Grade 4 Osteoarthritis with complete loss of joint space (bone-on-bone) or subchondral bone collapse, 2. Rheumatoid arthritis, or history of septic or reactive arthritis, 3. Gout or a history of gout or pseudogout in the affected knee, 4. Has more than two clinically relevant BMLs in the index knee, 5. Osteochondritis dissecans of the knee with significant bone loss, 6. Collapse of subchondral bone, 7. Clinically relevant BML located at ACL/PCL insertion, 8. MRI evidence of frank ligament instability, 3. Passive knee flexion \< 110° or flexion contracture \>30°, 4. History of systemic diseases which could contribute to secondary arthropathies (e.g., sickle cell disease, hemochromatosis, or autoimmune disease), 5. Has a neuromuscular, neurosensory, or musculoskeletal deficiency that limits the ability to perform objective functional assessment of either knee, 6. If diabetic, blood glucose over 200 mg/dL at time of enrollment, 7. Current daily tobacco or high nicotine product user or \< 3 months from nicotine cessation, 8. Presents a high surgical risk due to unstable cardiac and/or pulmonary disease, 9. Has HIV or other immunodeficient state including subjects on immunosuppressant therapies, or has significant illness (metastasis of any type) that decreases the probability of survival to the 2 year endpoint, 10. Is at substantial risk for the need of organ transplantation, such as renal insufficiency, 11. Is pregnant or breast-feeding at the time of surgery, 12. Has a history of any invasive malignancy (except non-melanoma skin cancer), unless treated with curative intent and with no clinical signs or symptoms of the malignancy for 5 years, 13. Has primary bone tumor in the knee area, 14. Anticipates having a lower extremity surgery other than the investigational surgery during the course of the study, 15. Is participating concurrently in another clinical trial, or has participated in a clinical trial within 30 days of surgery, 16. Is receiving prescription pain medication other than NSAIDs or acetaminophen for conditions unrelated to the index knee condition, chronic use of anticoagulants, or taking corticosteroids, 17. Active joint infection or history of chronic joint infection at the surgical site, 18. Prior total meniscectomy of index knee, 19. Has primarily patellofemoral symptoms, 20. Is indicated for concomitant procedures (i.e., microfracture, subchondral drilling, cartilage allograft, ligament or tendon repair, distal realignment/osteotomy, root repair) in the index knee, with the exception of incidental loose body removal, debridement, synovectomy, osteophyte removal in locations other than adjacent to BMLs, and/or partial meniscectomy, 21. Has contraindications for Magnetic Resonance Imaging (MRI), 22. Is receiving worker's compensation or is currently involved in litigation relating to the index knee, 23. Has a history of substance abuse.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone marrow edema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CORE Orthopaedic Medical Center

    Encinitas, California, 92024, United States

  • Emory University

    Atlanta, Georgia, 30329, United States

  • Foundation for Orthopaedic Research and Education

    Tampa, Florida, 33637, United States

  • Hawkins Foundation

    Greenville, South Carolina, 29615, United States

  • Loma Linda University Health System

    Loma Linda, California, 92354, United States

  • MedStar Health Research Institute

    Timonium, Maryland, 21093, United States

  • New Mexico Orthopaedic Fellowship Foundation

    Albuquerque, New Mexico, 87106, United States

  • Orthopedic Associates of Central Texas

    Austin, Texas, 78745, United States

  • Research St. Joseph's - Hamilton

    Hamilton, Ontario, L8N4A6, Canada

  • Rush University Medical Center

    Chicago, Illinois, 60612-3833, United States

  • Stanford University

    Stanford, California, 94305, United States

  • The Ohio State University

    Columbus, Ohio, 43202, United States

  • University of Virginia

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.